List of Biologics Companies in Taiwan - 18

Adimmune Corp (4142) is a biotechnology company based out of Taichung City, Taiwan.

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications.

Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

GlycoNex Inc. was founded in 2001, in alliance with The Biomembrane Institute (TBI) from Washington University and Dr. Sen-Itiroh Hakomori, a member of the National Academy of Sciences (USA). GlycoNex was the first pharmaceutical company in Taiwan to combine cancer-related glycan identification with human monoclonal antibody development. GlycoNex Inc. possesses a complete and detailed technological platform for anti-glycan antibody development, including multiple acquired licensed patents. Our pipeline consists of new drug development in parallel with biosimilars. Our new drugs were selected and developed through a detailed antigen/antibody characterization and cell line development. In 2009, we licensed GNX8 to Otsuka Pharmaceutical Co., Ltd. In 2019, our first-in-class new drug GNX102 received FDA IND approval. In 2020, we initiated our Clinical Trial Phase I dose-escalation study for GNX102 and received TFDA IND approval. In parallel, our biosimilar products Denosumab and Aflibercept have completed different volumes of pilot studies and data ready for review. We aim to look for opportunities of out-licensing our products or co-develop in cooperation.

HanchorBio (漢康生技) is developing a technology for the creation of next generation personalized biotherapeutics. Based in San Francisco, Taipei, and Shanghai, we are led by a group of pharmaceutical industry veterans with proven track-record of success is biologics discovery and global development with bold vision to rewrite immunotherapies. Committed to reactivating the immune system to fight against diseases, our proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to help revolutionize the treatment of people with cancer and other debilitating diseases. Our FBDB™ platform has successfully delivered proof-of-concept data in several in-vivo animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing methodology in CMC, we develop transformative medicines to address unmet medical needs.

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious new drugs and treatments to improve human health and well-being. The company focuses on drug pipelines, patents, clinical trials, and investment in the biopharmaceutical industry.

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

Established in 2012, Medigen Vaccine Biologics Corp (MVC) is a subsidiary of Medigen Biotechnology Corp (www.medigen.com.tw), Taipei, Taiwan. MVC develops vaccines and biosimilars for important unmet medical needs. Our focus is to deliver affordable medicines for developing countries and with a particular focus on SE Asia. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities. Humanity, innovation, and quality are MVC core values. We integrate biomedical technologies to improve human health so that every person, from infants to seniors, has a chance to be free from infectious diseases. Our most advanced products are MVC-1901 and MVC-EVA71. MVC-1901 is a spike-protein-based subunit vaccine for COVID-19. Based on a very large phase 2 trial powered to assess safety and efficacy by immunobridging, the vaccine has EUA status in Taiwan. Phase 3 trials for full approval are in progress. MVC-EVC71A is an inactivated whole virus-based vaccine for enteroviral disease in children between 2 months and 12 years of age. The vaccine has recently completed a phase 3 trial and is currently in regulatory review for commercial licensing.

OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway. In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile. OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.

Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology

PapiVax Biotech, Inc. (PBI) is a biotechnology company that intends to become a global leader in immunotherapy for chronic viral infections and related cancers through application of our state-of-the-art immunology and virology expertise, first to develop safe and effective treatments for human papillomavirus (HPV) infections and related cancers and then to expand application of our immunotherapy platforms against other chronic virus infection-related human cancers.

PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing, fully integrated global biopharmaceutical innovator. Leveraging proven scientific principles and deep expertise in commercializing medicines, the company aims to deliver biologics for challenging diseases in hematology, oncology and immunology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea.

Noticing that antibody drugs can effectively cure diseases but at the same time cause severe adverse effects because of on-target toxicity, PrecisemAb, just like our name "Precise + mAb", is committed to creating the safest antibody therapy for patients. Our Universal Antibody Lock technology could "inactivate" antibody's binding ability by giving it a "Lock" on the biding site. The binding ability of antibody is limited in healthy tissues unless antibody encounters disease-associated protease in the diseased site. The cleaved Lock-antibody is designed to be specifically activated and neutralize the target antigen to inhibit the disease progression. Therefore, our antibody lock technology can effectively enhance antibody drugs’ selectivity in disease area and consequently reduce side effects caused by on-target toxicity. We at PrecisemAb deeply believe in scientific thinking and cultural diversity since innovations always come from diversity, and scientific mind can transform creativities into practical solutions. This belief is not only applied to how we work internally but also how we collaborate with external partners and how we contribute back to our society.

Steminent Biotherapeutics Inc. is the leading stem cell clinical development company in Taipei, with subsidiaries in San Diego and Shanghai, dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes advanced, proprietary processes and know how to isolate, purify, amplify and manufacture standardized stem cell products of the highest quality for research and clinical development in multiple indications. Steminent’s Stemchymal® allogeneic cell therapy R&D program has generated a portfolio of clinical stage therapeutic candidates for multiple diseases including: Phase II; Spinocerebellar Ataxia (PolyQ SCA), Phase I; Osteoarthritis of the Knee, and Phase I: Acute Liver Failure. 幹細胞醫藥產業先驅的仲恩生醫，以推動異體間葉幹細胞治療為核心，擁有世界一流的幹細胞研發團隊與技術。獨家核心技術平台Stemchymal®，以領先全球的幹細胞分離、純化、增生技術，應用於自體及異體的脂肪間葉幹細胞治療。 仲恩生醫以最嚴謹的製藥規範與品質管理，不斷累積科學實證，並透過國內外頂尖醫學中心臨床試驗證實仲恩生醫幹細胞產品的安全與療效。除此，仲恩生醫透過與臨床醫師及國內外合作夥伴緊密的合作，持續地針對臨床未被滿足的需求，持續開發Stemchymal®優質細胞產品於急性肝衰竭及其他適應症之應用，期許未來多國的二期臨床試驗的結果，以及在其他不治和難治病症上的努力和不斷的進步，將可盡早實現幹細胞藥物在臨床應用的價值，嘉惠無藥可醫之病患。 2016年藉由台日再生醫療的策略結盟，深化台日雙方的合作關係，更促進再生醫學產業化和實用化的發展。2018年向美日兩國申請的臨床試驗二期申請案，相繼於7月14日和7月29日正式通過。一旦於日本完成異體間葉幹細胞新藥的二期臨床試驗，將依日本再生醫藥專法申請孤兒藥資格及最高7至10年暫時性藥證許可。

TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch.

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need. With Taiwan as our home base, we have successfully recruited many experts and consultants in new drug development worldwide. With our extensive experience and expertise in drug development, we can rapidly add value to our product line by moving the progress of our drug products forward. We are committed to our pursuit of high quality and scientific excellence, and establishing global collaboration and partnering. Our goal is to become a global drug development company and deliver new therapeutic hopes for the severe diseases.

United BioPharma (UBP) was established in September 2013 as a spinoff company from UBI which was founded in 1985 in the USA. UBP focuses on developing, manufacturing, and marketing integrated therapeutic mAb products and related technologies. In addition, UBP also provides fully integrated and high-quality CDMO services. We commit to meeting our client's needs. Among +250 employees, 50% are in R&D and 65% have a master’s degree or higher. Global facilities of UBP include clinical development, R&D, manufacturing centers in Taiwan and China, as well as business centers in the USA and Taiwan.